Thus, hypermethylation of the MGMT gene promoter can confer a greater sensitivity of the tumor cell to pharmacological treatment with TMZ, and the MGMT promoter methylation status is currently used as a predictor for the benefit of TMZ therapy [1,2]. This evidence concerns the gene MGMT and neoplasm.